Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 42

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 42
---
in
anticipates that its first therapeutic regimen to enter clinical trials within the next 2 – 3 years, with potential
regulatory approval in the next 8 – 11 years.

For a description of the regulatory steps for the implementation of
Darnatein’s strategy described above, see “Business of the Company and Certain Information About the
Company — Vaximm — Regulatory Steps”.

Intellectual Property

Darnatein owns exclusive intellectual property rights covered under
2 patent families relating to DRT-101, DRT-102 and other associated candidates filed in the United States and across major markets,
including Europe, China, India, and Japan. This patent family covers composition of matter, with a priority date of 2019 and estimated
expiry in 2039, not including potential patent term adjustments or patent term extensions.

Designer ligands of TGF-ß superfamily
(Licensed Patent Rights) (0)
WO 2010/099219, Exclusive License Agreement between Joint Center for Biosciences and Darnatein

    Country
Code
     
    Type
     
    Filing date
     
    Filing no.
     
    Grant Date
     
    Grant no.
     
    Publ. No.
     
    Expiry
     
    Status
  
    WO
     
    PCT
     
    24/02/2010
     
    PCT/US2010/025260

    2010/099219

    EP
     
    PCT
     
    24/02/2010
     
    10746779
     
    10/02/2016
     
    2401293B1
     
    2401293
     
    24/02/2030
     
    granted
  
    KR
     
    PCT
     
    24/02/2010
     
    1020117021911
     
    12/10/2015
     
    1015586420000
     
    1020110121642
     
    24/02/2030
     
    granted
  
    CA
     
    PCT
     
    24/02/2010
     
    2752647A